Literature DB >> 34844771

Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine.

Kodai Kuriyama1, Yoshimi Kitamura2, Taisuke Tsuji3, Rina Nishikawa4, Hiroaki Nagata4, Muneo Ohshiro4, Mio Sugitani4, Yoshiko Hirakawa4, Yosuke Matsumoto4, Toshiki Iwai4, Hitoji Uchiyama4.   

Abstract

We herein report the rare case of a 72-year-old female who presented with paraneoplastic pemphigus (PNP) and bronchiolitis obliterans (BO) associated with follicular lymphoma (FL), who was successfully treated with obinutuzumab (GA101; G) and bendamustine (B). The patient had severe erosive stomatitis and bilateral conjunctival hyperemia that persisted for more than 6 months. A huge mass was found in the abdominal cavity, and a biopsy revealed grade 1 FL (stage IV). Based on a lip biopsy result, the patient was diagnosed with PNP associated FL. The patient received bendamustine and obinutuzumab (BG) chemotherapy and FL and PNP responded very well, but BO was additionally associated during the course of BG. BO progressed without exacerbation as BG therapy progressed to a 2 year maintenance therapy with G, and combination of azithromycin, inhaled bronchodilator therapy, and corticosteroid. She was followed up at the outpatient department with no pulmonary function decline or FL and PNP recurrence. Our case suggests that BG could be a promising treatment option for PNP and BO.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bendamustine; Bronchiolitis obliterans; Follicular lymphoma; Obinutuzumab; Paraneoplastic pemphigus

Mesh:

Substances:

Year:  2021        PMID: 34844771     DOI: 10.1016/j.currproblcancer.2021.100813

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  2 in total

1.  Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes.

Authors:  Thilo Gambichler; Yi-Pei Lee; Ilske Oschlies; Christina H Scheel; Wolfram Klapper; Nico Nowack; Martin Doerler; Markus Stücker; Nasreddin Abolmaali; Laura Susok
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

2.  Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus.

Authors:  Johanna Freund; Franz Trautinger; Gerhard Kopetzky; Knut Prillinger
Journal:  JAAD Case Rep       Date:  2022-07-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.